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We have developed a radioimmunoassay method (RIA) to mea- 
sure urinary albumin excretion. We determined the albumin excretion 
rate (AER) (~g/min) of 122 healthy subjects and ~ 45 diabetic patients 
(115 type I, 30 type ll). The results indicate that the RIA is sensitive 
(0.39 +-- 0.08 rag/L), precise (CV 5-8%), and gives reliable results 
on previously frozen urine samples. The distribution of the AER val- 
ues in healthy subjects and diabetic patients was not normal, It was 
normalized by log or square-root ransformation of the data. Seventy- 
three percent of diabetic patients lay within the normal range (0.6- 
10.6 ~g/rnin). Twenty percent could be considered "at risk" to de- 
velop overt diabetic nephropathy because their albuminuria ex- 
ceeded a threshold level of 15 l~g/min chosen previously as the 
cutoff value for microalbuminuria. 
We found no correlation between AER and glycated hemoglobin, 
and only a weak correlation between AER and diabetes duration in 
type I diabetic patients. 
KEY WORDS: urinary albumin; microalbuminuria; AER; 
diabetic nephropathy; diabetes mellitus; radioimmunoassay. 
M icroalbuminuria is defined as an increased uri- nary albumin excretion rate (AER) that is above 
the upper normal imit, but not detectable by standard 
clinical tests such as Albustix (Miles GmbH, Sparte 
Ames, Frankfurt, West Germany) (1-2). 
The clinical relevance and usefulness of the mea- 
surement of microalbuminuria as a predictor of overt 
diabetic nephropathy has been assessed by long-term 
prospective studies performed both in type I, insulin- 
dependent (3-5) and in type II, maturity-onset diabetic 
subjects (6). These studies have shown that micro- 
albuminuria is strongly prognostic of persistent, A1- 
bustix-positive proteinuria, the hallmark and starting 
point of clinical diabetic nephropathy (3-6). In addi- 
tion, microalbuminuria, both in type I and in type II 
diabetic patients, has been shown to predict increased 
mortality not only of renal origin, but also from cardio- 
vascular disease (6,7). 
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*In our laboratory, the normal range of HbAlc is 4 to 6%. 
Several methods, among which radial immunodif- 
fusion (8) and radioimmunoassay (9-12) have been the 
most widely used, can measure small concentrations of 
albumin in urine. Until now however, they have been 
limited to a few research laboratories (12). With the 
availability of new commercial kits for the RIA as- 
sessment of albuminuria, more extensive studies on the 
util ity of microalbuminuria as a marker of clinical ne- 
phropathy is possible. Issues to be resolved are the dis- 
tribution of AER values in normal and diabetic subjects 
(13), the development ofnormal ranges, the day-to-day 
variability of urinary albumin excretion (14), and the 
mode of collection and storage of urine samples. In this 
article, we describe the characteristics of the RIA method 
developed in our laboratory and report results that ad- 
dress these issues. 
Materials and methods 
SUBJECTS 
Urinary albumin excretion was measured in 122 
healthy subjects (58 males and 64 females; age, 16-59 
years; m +- SD, 29.6 - 8.5) in 115 type I, insulin-de- 
pendent diabetic patients (51 males and 64 females; 
age, 9-66 years; 31.1 +- 14; duration of diabetes: 1-37 
years, 11.2 +- 7.5; fasting plasma glucose: 4.4-7.7 mmol/ 
L; glycated hemoglobin, HbAlc: 4.5-11%, 7.6 +- 1.3)*, 
and in 30 type II, maturity-onset diabetic patients (16 
males and 14 females; age, 25-72 years, 50.4 +- 11.1; 
diabetes duration: 1-39 years, 9.9 -+ 8; fasting plasma 
glucose: 5-7.7 mmol/L; HbAlc: 5-10%, 7.6 +- 1.5). All 
the subjects studied were within 10% of ideal body 
weight, had no history of renal or urinary tract disease, 
and had negative urine cultures. They were Albustix- 
negative, normotensive, and with normal renal func- 
tion (creatinine clearance in normals, type I and II di- 
abetics was 2.02 -+ 0.6 × 10-3; 1.98 --- 0.41 × 10-3; 1.95 
+- 0.41 x 10 -3 L/s, respectively). Timed, overnight ur- 
ine collections were used (3). Every subject collected 
urine for at least three consecutive nights. Albumin 
was measured on each of these specimens, and the mean 
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value was expressed as AER in ~g/min. All urines were 
collected in plastic tubes with no additive or preserv- 
ative and stored at -20°C until assayed. 
RIA SYSTEM 
The standard for the RIA is purified human serum 
albumin (HSA) (HSA, crystallized and lyophilized, es- 
sentially globulin-free; Sigma, St. Louis, MO 63178). 
125-I-HSA is the tracer and a specific anti-HSA serum, 
(Sclavo S.p.A., Cinisello Balsamo, Italy) is the antibody. 
The separation of the bound from the free phase is by 
second antibody (goat anti-rabbit-gamma globulins di- 
luted 1:100 in the Tris-EDTA buffer) plus PEG (8% 
polyethylene glycol in Tris 0.05 M, pH 8.6 buffer). 
The standard curve is prepared by diluting a solution 
(100 mg/L) of purified HSA with Tris-EDTA buffer (Tris 
buffer 0.1 M, pH 8.6, with EDTA 0.02 M, sodium azide 
1 g/L, and gelatin 2 g/L) to give seven standards, con- 
taining 3, 5, 10, 15, 20, 30, and 50 mg/L of HSA, re- 
spectively (Figure 1); 25 ~L of each is used in the assay. 
The 125-I-HSA is prepared by the Chloroamine-T- 
method (15). The specific activity obtained after chro- 
matographic purification on Sephadex G75 column was 
30 to 40 ~Ci/~g. A solution containing 3 to 4 x 104 
cpm in 100 ~L (about 10 ~g/L of 125-I-USA in the Tris- 
EDTA buffer) is used in the assay. The antiserum was 
raised in rabbits and diluted 1 : 1000 with the Tris-EDTA 
buffer. The bovine serum albumin (BSA for RIA assay, 
Miles Laboratories, Inc., Naperville, IL 60566) shows 
no crossreactivity (B/B0 < 5%) up to a concentration f 
100 g/L. There is negligible crossreactivity also with 
human gamma globulin (0.3%) and human transferrin 
(<0.01%). 
The assay is performed as follows: 25 ~L of the stan- 
dard solution or undiluted urine sample, 100 ~L of the 
antiserum and 100 ~L of the second antibody are added 
to each tube. After mixing, the tubes are incubated (1 
h) at room temperature (18-22°C). Two mL of PEG 
solution are added to each tube and after centrifugation 
(1500 x g for 10 min at 4°C), the supernates are re- 
moved by aspiration and the precipitates counted in a 
well-type gamma counter. All sample values, the index 
of sensitivity, the precision profile, and the quality con- 
trol of the assay are calculated using a previously de- 
scribed data validation program (16). An AER cutoff 
value of 15 ~g/min was chosen for diagnosis of mi- 
croalbuminuria (5,6). Statistical analysis of the pa- 
tients, data was performed using a standard statistical 
package (17) on an IBM 370. 
Resu l ts  
RIA SYSTEM 
Figure 1 shows the mean standard curve (-SD), the 
mean precision profile, the mean degree of sensitivity, 
the mean binding capacity (Bo/T), and the mean per- 
cent nonspecific ounts (N/T) of our RIA system, ob- 
tained from 40 different assays performed over 18 
months. The degree of precision and sensitivity permits 
the measurement of AER even in normal subjects. How- 
ever, when necessary, 50 or 100 ~L of urine samples, 
instead of 25 ~L, may be assayed. 
A linear response (r > 0.98) was obtained when in- 
creasing volumes of eight different urinary samples 
containing albumin concentrations from 20 to 130 mg/ 
L were assayed. Urine samples containing very high 
albumin concentrations may be diluted for the assay. 
Quantitative recovery was obtained when known 
amounts of purified HSA were added to three different 
urine samples (two assayed after storage at - 20°C and 
MEAN STANDARD CURVE (_+SD.n=40) MEAN PRECISION PROFILE ("+SO, n= 40) 
B/B % 
100 
90 
80 
70 
60 
50. 
40  
30 
20 
10 
N/T% =1.81"+0.38 
Bo/T% = 6780 +_ 6.10 
Sens. =0.39"+0.08 mg/L 
CV% 
11. 
10 
9 
8 
7 
6 
5 
4 
3 
2 
10 20 30 40 50 60 70 80 90 100 0 10 20 30 40 50 60 70 80 90 100 
ALBUMIN ADDED, mg/L  ALBUMIN ADDED, mg/L '~ 
Figure l IMean (-+SD) standard curve, mean precision profile, mean degree of sensitivity, mean binding capacity (Bo/T) and 
mean aspecific ounts (N/T) of our RIA method obtained in different 40 experiments during 18 month-period. 
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TABLE 1 
Stability of Urinary Albumin Value (~g/ml) in Multiple Thawing and Freezing Experiments 
Performed During a Three Week Period 
4 days 8 days 15 days 21 days 
Sample Fresh (first thawing) (second thawing) (third thawing) (fourth thawing) 
1 2.30 2.16 1.97 2.47 2.21 
2 11.40 8.80 8.33 9.75 9.37 
3 27.60 25.70 26.16 25.79 26.68 
4 12.80 13.03 12.93 12.41 13.19 
5 7.94 7.46 6.83 7.45 7.90 
6 1.97 2.10 1.58 2.17 1.76 
7 6.25 5.67 5.30 5.29 5.34 
8 40.70 37.57 34.05 38.39 40.29 
9 6.80 6.70 6.26 6.24 6.00 
10 45.62 47.19 50.32 47.50 48.45 
Mean 16.34 15.64 15.37 15.75 16.12 
SD 15.92 15.78 16.22 15.97 16.6 
NOTE: Each urine sample has been measured first at fresh, and then after four repeated freezing 
and thawing experiments. 
one without freezing), mean percent recovery ranging 
from 98 to 103%. 
The between-batch precision was assessed by assay- 
ing three urine pools over several months (16 months: 
pool A and B; 8 months: pool C). The method shows 
good precision (CV ranging between 5-8%). Significant 
degradation of immunoreactive endogenous HSA was 
not observed in stored urine samples during the study. 
We found no reduction of measured albumin in sev- 
eral (n --- 4) freezing and thawing experiments per- 
formed in 10 urines over three weeks (Table 1), and no 
significant differences were found between eight urine 
samples assayed before (mean 11.1 +- 6.7 mg/L) and 
after centrifugation (mean 11.3 + 6.5 mg/L). 
Clinical results 
The distribution of AER values in the 122 normal 
subjects i  not Gaussian (Figure 2A) (p < 0.013, test di 
S0mers) (18), and the log transformation f data did not 
normalize the curve (p < 0.01, Figure 2B). A normal 
distribution was achieved after the square-root trans- 
formation of AER values (Figure 2C). 
The range of AER in healthy control subjects was 0.6 
to 10.6 ~g/min ( lst -99th percentile) with a mean value 
of 4.42 +_ 1.99 ~g/min (median 4.27) (Table 2). 
In diabetic patients, the mean AER was 12 ~g/min, 
(range 1-110) and about 70% were within normal imits 
(Figure 3). The mean AER of both type I (12.5 ~g/min, 
range 1.3-110) and type II (10 ~g/min, range 1-39) 
diabetic patients was significantly higher than the AER 
of normal subjects (p < 0.001). 
In 92 normoalbuminuric type I diabetic patients, the 
AER was 6.3 - 2.8 ~g/min (range 1.3-13.6). In the 24 
normoalbuminuric type II diabetics, the AER was 
5.2 + 3.3 ~g/min (range 1-14). The AER of normo- 
albuminuric type I and type II diabetic patients was 
significantly higher than that of the controls, (p < 
0.01, one-way ANOVA), but the data from the two 
groups of diabetics did not differ (Table 2). 
TABLE 2 
Clinical and Metabolic Characteristics of Subjects Studied 
Control Subjects 
(n = 122) 
Type I 
Normo- 
albuminuria 
(<15 ~g/min) 
(n = 92) 
Micro- 
albuminuria 
(>15 ~g/min) 
(n = 23) 
Diabetic Patients 
(n = 145) 
Type II 
Normo- 
albuminuria 
(<15 ~g/min) 
(n = 24) 
Micro- 
albuminuria 
(>15 ~g/min) 
(n = 6) 
Sex (M:F) 58/64 42/50 9/14 12/12 4/2 
Age (years) 29.6(16-59) 29(9-66) 39(16-65) 50(27-72) 51(25-63) 
Duration of diabetes - -  10(1-28) 15(2-37) 9(1-39) 12(1-22) 
Albumin Excretion 4.42(0.6-10.6) 6.3(1.3-13.6) a 36.9(15-110) 5.2(1-14) a 26(18-39) 
Rate (AER) (~g/min) 
Creatinine Clearance 2.02(1.20-3.31) b 1.93(0.86-3.28) b 2.16(1.48-3.28) b 1.83(1.46-2.16) b 2.08(1.28-2.93) b 
(L/s) 
HbAlc (%) 5.2(4.5-5.9) 7.6(4.5-11) a 7.9(6.7-10.3) ~ 7.9(5.6-10.2) ~ 7.0(4.4-8.4) ~
NOTE: Results are expressed as means with ranges in parentheses. 
ap < 0.01 vs normal subjects. 
b×lO-3" 
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Figure 2--(A) Distribution of AER data in 122 normal sub- 
jects, (B) log-transformation, and (C) square-root transfor- 
mation of values. Only the last distribution was not signifi- 
cantly different from a normal one. 
The mean AER of microalbuminuric type I patients 
(36.9 -- 28 ixg/min; range 15-110) also did not differ 
significantly from that found in microalbuminuric type 
II diabetics (26 --+ 7.4 txg/min; range 18-39) (Table 2). 
After the exclusion of the microalbuminuric patients 
(AER > 15 I~g/min; n = 29), both log and square-root 
transformations ormalized the AER distribution in di- 
abetic subjects. We found a weak (r = 0.25, p < 0.02; 
n = 115) correlation between the duration of diabetes 
and AER in type I diabetic patients but no such rela- 
tionship between glycated hemoglobin and AER values 
in these patients. 
In normal and in diabetic subjects, the mean coeffi- 
cient of variation of the AER was about 30% (range 29-  
33%), and that of urine volumes ranged between 21 and 
26%. 
Discussion 
The RIA method is rapid, sensitive, acceptably pre- 
cise, and has a wide l inear dynamic range. Urine sam- 
ples can be preserved without additives, with no loss 
of immunoreactive ur inary albumin concentration, and 
the assay may be performed on prefrozen urine samples. 
The best type of urine collection (e.g., 24 h or overnight 
collection, morning or random urine samples, forced 
diuresis) has yet to be decided (13-14,19-21). Day-to- 
day and intra-day variation of ur inary protein excre- 
tion, including albumin, is a well-documented phenom- 
enon (22). In our study, the mean coefficient of variation 
of the AER (29-33%) compares favorably with that re- 
ported in other studies employing overnight collection 
(2,3,13,21,23), and in our opinion overnight urine col- 
lection is suitable for the measurement of microalbu- 
minuria and we recommend the collection of a mini- 
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Figure 3--AER values in normal and diabetic subjects. Each 
bar represents he corresponding mean value. 
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mum of three consecutive overnight urine samples 
(13,14,19,24), in order to accurately assess the AER. 
AER values obtained in our normal subjects (4.42 --- 
1.99 ~g/min) are similar to those found by others (Mo- 
gensen: 4.3 -+ 1.3 ~g/min, (1,5); Hemmingsen and Skaa- 
rup: 4.31 ~g/min, ref. 22), but are lower than those 
found from others (Viberti et al.: 6.6 -+ 3.2 ~g/min; (25); 
Brodows et al.: 6.5 +- 2.2 }xg/min, ref. 12). These dif- 
ferences confirm how important i is for each laboratory 
involved in an AER study (1,5,12,22,25,26) to have their 
own normal range calculated on a proper group of healthy 
controls. Data from our 122 healthy subjects confirm 
that the distribution of urinary albumin excretion is 
not Gaussian (23,24,26-28). 
For statistical analysis of albuminuria values, it is 
advisable to employ nonparametric methods or, alter- 
natively, to try to normalize data by log or square-root 
(as in our case) transformation. 
Diabetics (type I and type II) showed a mean AER 
significantly higher than normals even after excluding 
the microalbuminuric subjects (Figure 3 and Table 2), 
because 27% of diabetics exceeded the upper normal 
limit (Figure 3). A weak correlation between the dia- 
betes duration and the AER was found only in type I 
patients, in accordance with other authors (26,27,29). 
We observed no correlation between AER and HbAlc 
in diabetics possibly due to their narrow range of gly- 
cated hemoglobin. Most values ranged between 7 to 
10%. In studies howing a correlation between AER and 
gbA1 (27,30), patients with very high HbA1 levels had 
been included. 
By our RIA, urinary albumin measurement is accu- 
rate and sensitive. Hence, the method may be used for 
transversal and longitudinal studies of diabetic ne- 
phropathy (31-35), if urines are collected by a stan- 
dardized procedure (27,36,37). 
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